2023
Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
Kim I. Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT. Investigative And Clinical Urology 2023, 64: 310-311. PMID: 37417555, PMCID: PMC10330420, DOI: 10.4111/icu.20230178.Peer-Reviewed Original ResearchMeSH KeywordsEarly Detection of CancerHumansMaleMass ScreeningProstate-Specific AntigenProstatic Neoplasms
2022
Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve
Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve. Journal Of Endourology 2022, 36: 1285-1289. PMID: 35906798, PMCID: PMC9587764, DOI: 10.1089/end.2021.0885.Peer-Reviewed Original ResearchMeSH KeywordsHumansLearning CurveMaleMiddle AgedProstateProstate-Specific AntigenProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresRoboticsTreatment OutcomeConceptsRobot-assisted radical prostatectomyShort-term outcomesCase seriesRadical prostatectomyAcceptable short-term outcomesSurgeon 2Average prostate weightLearning curveMedian patient ageClavien-Dindo scaleMedian operating timeTotal postoperative complicationsShorter hospital stayLarge case seriesOperating timeProstate-specific antigenRobotic radical prostatectomyInstitutional review boardSignificant learning curveHospital stayMedian followPostoperative complicationsIntraoperative complicationsPerioperative outcomesBlood loss
2020
Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation
Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation. Cancer 2020, 126: 5114-5123. PMID: 32888321, DOI: 10.1002/cncr.33179.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceProstate cancerSurvival disparitiesWhite menProstate cancer screening recommendationsBlack menPCa-specific survivalAdverse clinical featuresCancer screening recommendationsEnd Results (SEER) databaseYear of diagnosisProstate-specific antigenClinical featuresScreening recommendationsResults databaseSurvival outcomesGrade CGrade D.White individualsMenRacial discrepanciesSurvivalTask ForceOutcomesTotal
2019
Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? Cancer 2019, 125: 2318-2320. PMID: 30861093, DOI: 10.1002/cncr.32054.Peer-Reviewed Original Research
2016
Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle
Patel R, Modi P, Elsamra S, Kim I. Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle. Journal Of Endourology 2016, 30: 709-713. PMID: 27072291, DOI: 10.1089/end.2016.0046.Peer-Reviewed Original ResearchMeSH KeywordsCarboxymethylcellulose SodiumErectile DysfunctionHumansHyaluronic AcidKaplan-Meier EstimateLaparoscopyMaleMiddle AgedNeoplasm Recurrence, LocalPenile ErectionPostoperative PeriodProspective StudiesProstate-Specific AntigenProstatectomyProstatic NeoplasmsRetrospective StudiesRobotic Surgical ProceduresTreatment OutcomeConceptsErectile functionNeurovascular bundleBiochemical recurrenceGood baseline erectile functionPreoperative prostate-specific antigenRobot-assisted laparoscopic prostatectomyBaseline erectile functionPreoperative SHIM scoreSexual Health InventoryAUA symptom scorePostoperative erectile functionKaplan-Meier analysisNerve-sparing prostatectomyProstate-specific antigenSignificant differencesMean SHIMSHIM scoreIndependent t-testMedian followOncologic outcomesConsecutive patientsOperative timeRetrospective reviewProstate sizeSymptom scores
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levelsRefining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score
Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDisease-Free SurvivalHumansKallikreinsKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicProstate-Specific AntigenProstatectomyProstatic NeoplasmsRadiation OncologyRadiotherapy, AdjuvantRetrospective StudiesSocieties, MedicalUnited StatesUrologyConceptsPositive surgical marginsGleason score 6Adjuvant radiotherapyGleason score 8BCR-free survivalRadical prostatectomyBiochemical recurrenceAmerican Urological AssociationPathologic stageGleason scoreScore 6BCR rateSurgical marginsScore 8Urological AssociationPathologic Gleason score 8Multivariate Cox regression analysisPathologic Gleason scoreSurgical margin statusCox regression analysisRadiation Oncology guidelinesAmerican SocietyASTRO guidelineIndependent predictorsMargin statusNeutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer
Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerAbsolute lymphocyte countAbsolute neutrophil countLow-risk prostate cancer patientsProstate cancer patientsProstate cancerLymphocyte countANC groupLymphocyte ratioBiochemical recurrenceCancer patientsActive surveillanceHigher prostate-specific antigen levelMetastatic castration-resistant prostate cancerLow-risk PCa patientsProstate-specific antigen levelHigh absolute lymphocyte countCastration-resistant prostate cancerBiochemical recurrence-free survivalRobot-assisted radical prostatectomyAdverse pathologic outcomesAppropriate patient selectionKaplan-Meier methodRecurrence-free survivalRisk stratification toolLower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics
Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.Peer-Reviewed Original ResearchConceptsProstate cancerClinicopathological characteristicsElevated prostate-specific antigen levelsProstate-specific antigen levelBenign prostatic hyperplasia patientsNon-metastatic diseaseAggressive clinicopathologic featuresLow PSA levelsSpecific antigen levelsProstatic hyperplasia patientsAggressive clinicopathological characteristicsLow Gleason scoreHuman prostate cancerCharacteristic curve analysisProstate cancer susceptibilityPSA levelsMetastatic diseasePCa patientsClinicopathologic featuresHyperplasia patientsAntigen levelsGleason scoreClinicopathological parametersPCa tissuesReal-time PCRPathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.
Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Urologica E Nefrologica 2015, 67: 1-9. PMID: 25664959.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyRadical prostatectomyActive surveillanceAdvanced diseaseUnderwent robot-assisted radical prostatectomyLow-risk prostate cancerLower prostate volumePSA density levelsLow-risk diseaseActive surveillance cohortOrgan-confined diseaseSpecimens of patientsAdvanced pathologic featuresProspective cohortAdditional patientsPathologic featuresPathologic findingsProstate volumeSingle centerProspective studyGleason scoreSurveillance cohortDefinitive interventionClinicopathological resultsPathologic analysis
2014
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapyReply
Ha Y, Kim I. Reply. Urology 2014, 84: 372. PMID: 24925832, DOI: 10.1016/j.urology.2014.02.040.Peer-Reviewed Original Research
2013
Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts
Kang D, Chung J, Ha H, Min K, Yoon J, Kim W, Seo W, Kang P, Jung S, Kim I. Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts. Asian Pacific Journal Of Cancer Prevention 2013, 14: 6913-6917. PMID: 24377625, DOI: 10.7314/apjcp.2013.14.11.6913.Peer-Reviewed Original ResearchMeSH KeywordsAgedAsian PeopleBlack PeopleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProstate-Specific AntigenProstatectomyProstatic NeoplasmsWhite PeopleConceptsBody mass indexHigh Gleason scoreGleason scoreProstate cancerT stageRadical prostatectomyPreoperative prostate-specific antigen levelProstate cancer treatment strategiesProstate-specific antigen levelMean body mass indexKorean prostate cancer patientsMean preoperative PSAWorse disease characteristicsAdvanced prostate cancerPathological T stageHigher T stageProstate cancer patientsHigher PSA valuesMalignant prostate cancerCancer treatment strategiesPreoperative PSAMass indexProstate sizePSA testPSA valuesDiagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer
Kang H, Yang J, Kwon W, Lee Y, Kim W, Kim Y, Yun S, Lee S, Kim I, Kim W. Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer. Journal Of Korean Medical Science 2013, 28: 1796-1800. PMID: 24339711, PMCID: PMC3857377, DOI: 10.3346/jkms.2013.28.12.1796.Peer-Reviewed Original ResearchConceptsProstate-specific antigen densityTUR specimensElderly patientsPSA levelsGleason scoreProstate cancerBiopsy coresHigher prostate-specific antigen levelProstate-specific antigen levelElderly comorbid patientsRoutine prostate biopsySignificant co morbiditySpecific antigen densityHigh clinical suspicionSpecific antigen levelsProstatic needle biopsyPrebiopsy PSA levelProstate cancer diagnosisTUR specimenClinical suspicionCo morbiditiesPathologic reviewComorbid patientsTransurethral resectionAntigen levelsEnrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion
Bansal N, Davis S, Tereshchenko I, Budak‐Alpdogan T, Zhong H, Stein M, Kim I, DiPaola R, Bertino J, Sabaawy H. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. The Prostate 2013, 74: 187-200. PMID: 24154958, PMCID: PMC3939797, DOI: 10.1002/pros.22740.Peer-Reviewed Original ResearchIncidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance
Park H, Ha Y, Park S, Kim Y, Lee T, Kim J, Lee D, Kim W, Kim I. Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance. Urologia Internationalis 2013, 90: 301-305. PMID: 23391718, DOI: 10.1159/000345292.Peer-Reviewed Original ResearchConceptsGleason score 3Prostate cancerRadical prostatectomyActive surveillanceScore 3Positive coresIncidence of upstagingPrediction of upgradingPSA cutoff levelPreoperative PSA levelUpstaging ratePSA levelsCancer involvementClinical stageNeedle biopsyUpstagingPatientsCutoff levelBiopsyMarginal associationIncidenceOverall rateCancerSurveillanceProstatectomy
2011
Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.
Kang D, Jang T, Jeong J, Choi E, Johnson K, Lee D, Kim W, Kim I. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian Journal Of Andrology 2011, 13: 838-41. PMID: 21785442, PMCID: PMC3739560, DOI: 10.1038/aja.2011.54.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedHumansMaleMiddle AgedPopulation SurveillanceProstate-Specific AntigenProstatectomyProstatic NeoplasmsConceptsActive surveillance criteriaActive surveillancePSA levelsSurveillance criteriaRadical prostatectomyLow-risk prostate cancerProstate-specific antigen levelRate of upstagingRisk of upstagingActive surveillance protocolsAcceptable treatment optionRisk of upgradingProportion of menNational Cancer InstituteCalifornia San FranciscoRisk of menContext of PSAPathological findingsAntigen levelsBiochemical recurrencePathological characteristicsSurveillance protocolTreatment optionsProstate cancerInclusion criteria
2004
Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy
Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63: 1191-1197. PMID: 15183988, DOI: 10.1016/j.urology.2003.12.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDisease ProgressionFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedMultivariate AnalysisNeoplasm StagingProstateProstate-Specific AntigenProstatectomyProstatic HyperplasiaProstatic NeoplasmsReceptors, Transforming Growth Factor betaTransforming Growth Factor betaTransforming Growth Factor beta1ConceptsPlasma TGF-beta1 levelsTGF-beta1 levelsAbnormal expressionTGFbeta-RIITGFbeta-RIBiochemical progressionRadical prostatectomyProstate cancerPathologic Gleason scoreSeminal vesicle involvementSurgical margin statusProstate cancer featuresTissue expressionGrowth factor-β1TGF-beta1 overexpressionConsecutive patientsExtracapsular diseaseMargin statusPathologic featuresGleason scoreBlood levelsLoss of expressionPrognostic markerImmunohistochemical stainingFactor-β1
2001
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.Peer-Reviewed Original ResearchConceptsProstate cancer metastaticPlasma TGFPreoperative plasma levelsRegional lymph nodesRadical prostatectomyCancer metastaticPSA progressionLymph nodesGleason sumPlasma levelsGrowth factorLocal-only failureOccult metastatic diseasePathologic Gleason sumPostoperative multivariate analysisOrgan-confined diseaseSurgical margin statusLymph node metastasisBiopsy Gleason sumRadical prostatectomy patientsProstate cancer invasionMetastatic diseaseBone metastasesConsecutive patientsMargin status
1995
Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
Lee C, Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136: 796-803. PMID: 7530653, DOI: 10.1210/endo.136.2.7530653.Peer-Reviewed Original ResearchConceptsHigher DHT concentrationsEffects of androgensConcentrations of dihydrotestosteroneDHT concentrationsPSA secretionAndrogen receptorCharcoal-stripped fetal bovine serumProstate-specific antigen (PSA) productionHuman prostatic cancer cell linesLow DHT concentrationsProstatic cancer cell linesDose-related mannerNuclear androgen receptorProstate-specific antigenCellular proliferationProstatic cancer cellsProduction of PSADose-dependent inductionWestern blot analysisCancer cell linesProportion of cellsDHT levelsLNCaP cellsM dihydrotestosteronePositive staining